Clinical trial NCT01242449: Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer
Official title: A Phase II Investigation of Oral Vinorelbine in Combination With Trastuzumab for 1st and 2nd Line Treatment of Women With Metastatic HER2 Positive Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Breast Cancer
Keywords: Breast cancer
Metastatic
HER2 positive
vinorelbine
Lead sponsor: Vejle Hospital
Sponsor class: OTHER
First posted: 2010-11-17
Enrollment: 10
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: This phase II study will investigate oral vinorelbine 90 mg/m2 on days 1 + 8 at 3 weeks intervals in combination with trastuzumab as 1st and 2nd line treatment of women with metastatic HER2 positive breast cancer.

Oral vinorelbine has shown the same overall response rate as i.v. vinorelbine in metastatic breast cancer, and capsules are generally better tolerated.


Eligibility criteria: Inclusion Criteria:

* Woman ≥ 18 years of age.
* PS 0-2. Expected lifetime of more than 12 weeks.
* Histologically verified breast cancer(adenocarcinoma)
* Primary tumor or metastasis is HER2 positive with IHC3+ or FISH+ (ratio ≥ 2.2).
* Documented metastatic breast cancer with min. one lesion measureable according to the RECIST 1.1 criteria. All solitary lesions must be verified cytologically/histologically if representing the only evidence of malignancy.
* The patient may have received (neo-) adjuvant chemotherapy (taxanes, anthracyclines and trastuzumab) and 1st line chemotherapy in combination with trastuzumab for metastatic disease.
* The patient may have received previous adjuvant antihormonal treatment for metastatic breast cancer.
* The patient may receive radiation therapy, however, not against lesions used for response evaluation.
* Normal heart function, LVEF ≥ 50% measured by MUGA/EKKO.
* Normal bone marrow function: Hemoglobin ≥ 6 mmol/l, ANC ≥ 1.5x10\^9/l. Thrombocytes ≥ 100x10\^9/l.
* Normal liver function: Bilirubin ≤ 1.5 x upper normal level, ALAT ≤ 2.5 x upper normal level, BASP ≤ 2.5 x upper normal level (≤ 5 if presence of bone metastases).
* Normal renal function: Creatinine ≤ upper normal level. In case of raised creatinine the measured/calculated GFR must be ≥ 50 ml/min.
* Fertile women must present a negative pregnancy test and use contraceptives during and 3 months after treatment. An IUD without hormone is considered a safe contraceptive.
* Written and orally informed consent prior to any study related procedure.

Exclusion Criteria:

* Local recurrence or counter-lateral breast cancer without other dissemination.
* Pregnant or breastfeeding women.
* Clinical symptoms of CNS metastases, incl. meningeal carcinomatosis.
* Malabsorption syndrome or other disease affecting the gastrointestinal function. Resection of the ventriculus or the small intestine, which can affect absorption of oral vinorelbine.
* Dysphagia or other conditions preventing the patient from swallowing tablets.
* Mental or social conditions preventing treatment or follow-up.
* Serious concurrent medical condition, such as:

  * AMI within 12 months or unstable angina.
  * Heart incompensation NYHA III or IV or uncontrolled hypertension (systolic \> 150 mm/hg and/or diastolic \>100 mm/hg).
  * Serious arrythmia requiring medication, excl. atrial fibrillation and paroxystic supraventricular tachycardia.
  * Active infection, uncontrolled diabetes or hypercalcemia.
* Other concurrent experimental treatment.
* Concurrent antihormonal treatment of metastatic breast cancer.
* Known neuropathia ≥ grade 2.
* Other previous malignant disease within the past 5 years excl. non-melanoma skin cancer and carcinoma in situ cervicis uteri.
* Previous treatment with vinca alkaloid.
* Previous serious allergic or unexpected reactions to trastuzumab treatment.

Primary outcomes:
measure: Objective Response Rate
timeFrame: Every 9 weeks. Up to 2 years
Secondary outcomes:
measure: Progression free survival
timeFrame: Every 9 weeks from date of first treatment until progression or death. Up to 2 years
measure: Overall Survival
timeFrame: From date of inclusion until date of death. Up to 2 years.
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Dept. of Oncology, Aalborg Sygehus
city: Esbjerg
country: Denmark
facility: Dept. of Oncology, Esbjerg Hospital
city: Vejle
country: Denmark
facility: Department of Oncology, Vejle Hospital
Study officials:
affiliation: Department of Oncology, Vejle Hospital
name: Troels Bechmann, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Oncology, Vejle Hospital
name: Erik H Jakobsen, MD
role: STUDY_CHAIR
References: